Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
17.71
-1.02 (-5.45%)
At close: Oct 29, 2025, 4:00 PM EDT
17.74
+0.03 (0.17%)
After-hours: Oct 29, 2025, 6:00 PM EDT
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
119.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 138.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TIL News
- 7 weeks ago - Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - GlobeNewsWire
- 2 months ago - Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - GlobeNewsWire
- 4 months ago - Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - GlobeNewsWire
- 5 months ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire
- 5 months ago - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 5 months ago - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success - Seeking Alpha